AI-native biotech Yudao Bio raises $30M Series C

What's the deal? Yudao Bio, an AI-native biotech company, has raised $30 million in a Series C round, co-led by Trustar CapitalDealroom has a profile for this one. Try Dealroom → and Decheng CapitalDealroom has a profile for this one. Try Dealroom →. Fortune CapitalDealroom has a profile for this one. Try Dealroom → and the Zhongsheng Xichuang Dingqi Fund joined as participating investors.

Who's involved? Trustar Capital announced the deal on September 15, saying it had signed a formal agreement for the round. Dianshi CapitalDealroom has a profile for this one. Try Dealroom → acted as long-term exclusive financial adviser.

The signal: The round reflects continued investor appetite for biotechs that build on artificial intelligence from the ground up, a segment drawing sustained venture backing as drug discovery increasingly incorporates computational methods.

Image credit: oakridgelabnews